Medical Therapy. Adverse Effects or Lack of Adverse Effects

Efficacy and Safety of IV Sildenafil in the Treatment of Newborn Infants with, or at Risk of, Persistent Pulmonary Hypertension of the Newborn (PPHN): A Multicenter, Randomized, Placebo-Controlled Trial

Christine M. Pierce, Min H. Zhang, Baldvin Jonsson, Dinu Iorga, Narayan Cheruvu, Cecile C. Balagtas, Robin H. SteinhornGreat Ormond Street Hospital for Children. Pfizer Inc. Karolinska Institute and University Hospital. Rady Children’s Hospital and University of California San Diego.United States Journal of PediatricsJ Pediatr 2021; 237: 154-161DOI: 10.1016/j.jpeds.2021.05.051 AbstractObjective: To investigate the efficacy and safety of sildenafil […]

Efficacy and Safety of IV Sildenafil in the Treatment of Newborn Infants with, or at Risk of, Persistent Pulmonary Hypertension of the Newborn (PPHN): A Multicenter, Randomized, Placebo-Controlled Trial Read More »

Clinical efficacy and safety of selexipag in children and young adults with idiopathic and heritable pulmonary arterial hypertension

Shinichi Takatsuki, Tomotaka Nakayama, Yurika Shimizu, Reiko Kawai, Hiroyuki MatsuuraToho University Omori Medical Center. Kochi Medical School Hospital.Japan Cardiology in the YoungCardiol Young 2023; 33: 196-200DOI: 10.1017/S1047951122000415 AbstractObjective: This study aimed to investigate the safety, tolerability, and efficacy of selexipag in children and young adults with idiopathic and heritable pulmonary arterial hypertension.Methods: This retrospective cohort study included clinical

Clinical efficacy and safety of selexipag in children and young adults with idiopathic and heritable pulmonary arterial hypertension Read More »

Safety and Feasibility of Riociguat Therapy for the Treatment of Chronic Pulmonary Arterial Hypertension in Infancy

Regan E. Geisinger, Amy H. Stanford, Brady Thomas, Steven H. Abman, Patrick J. McNammaraUniversity of Iowa. University of Colorado.United States Journal of PediatricsJ Pediatr 2022; DOI: 10.1016/j.jpeds.2022.11.026 AbstractThe effects of riociguat, an oral-soluble guanylate-cyclase stimulator, were studied in 10 infants with chronic pulmonary arterial hypertension. Respiratory status (n = 8/10), right heart dilation (n = 7/10),

Safety and Feasibility of Riociguat Therapy for the Treatment of Chronic Pulmonary Arterial Hypertension in Infancy Read More »

Riociguat in children with pulmonary arterial hypertension: The PATENT-CHILD study

Humberto García Aguilar, Matthias Gorenflo, D. Dunbar Ivy, Shahin Moledina, Biagio Castaldi, Hidekazu Ishida, Paweł Cześniewicz, Jacek Kusa, Oliver Miera, Joseph Pattathu, Ken‐Pen Weng, Laszlo Ablonczy, Christian Apitz, Marta Katona, Kenichi Kurosaki, Tomas Pulido, Hiroyuki Yamagishi, Kazushi Yasuda, Galia Cisternas, Melanie Goth, Susanne Lippert, Anna Radomskyj, Soundos Saleh, Stefan Willmann, Gabriela Wirsching, Damien Bonnet, Maurice

Riociguat in children with pulmonary arterial hypertension: The PATENT-CHILD study Read More »

Safety and tolerability of combination therapy with ambrisentan and tadalafil for the treatment of pulmonary arterial hypertension in children: Real-world experience

Azadeh Issapour, Benjamin Frank, Sarah Crook, Michelle D. Hite, Michelle L. Dorn, Erika B. Rosenzweig, D. Dunbar Ivy, Usha S. KrishnanColumbia University Irving Medical Center. University of Colorado and Children’s Hospital Colorado.United States Pediatric PulmonologyPediatr Pulmonol 2022; 57: 724-733DOI: 10.1002/ppul.25796 AbstractObjective: To describe the safety and tolerability of treatment with ambrisentan and tadalafil in pediatric pulmonary hypertension

Safety and tolerability of combination therapy with ambrisentan and tadalafil for the treatment of pulmonary arterial hypertension in children: Real-world experience Read More »

Abnormal platelet aggregation in pediatric pulmonary hypertension

Stephanie S. Handler, Jing Jin, Michelle T. Ogawa, Jeffrey A. Feinstein, Clara LoMedical College of Wisconsin. Stanford University.United States Pulmonary CirculationPulm Circ 2022; 12: DOI: 10.1002/pul2.12104 AbstractEndogenous prostacyclin stimulates pulmonary vasodilation and inhibits platelet aggregation. For the synthetic analog treprostinil, used in the treatment of pulmonary hypertension (PH), conflicting, anecdotal evidence exists regarding its effects on

Abnormal platelet aggregation in pediatric pulmonary hypertension Read More »

Inpatient Transition From Intravenous to Inhaled Treprostinil in a Pediatric Patient

David Procaccini, Dennis Delany, Abigail Self, Patricia Lawrence Kane, John D. CoulsonJohns Hopkins HospitalUnited States Journal of Pediatric Pharmacology and TherapeuticsJ Pediatr Pharmacol Ther 2023; 28: 102-107DOI: 10.5863/1551-6776-28.1.102 AbstractWe report a case of a 7-year old male with idiopathic pulmonary arterial hypertension, successfully transitioned from an intravenous infusion to inhaled treprostinil during inpatient admission, after his

Inpatient Transition From Intravenous to Inhaled Treprostinil in a Pediatric Patient Read More »

Multicenter review of a tadalafil suspension formulation for infants and children with pulmonary hypertension: A North American experience

David Edward Youssef, Stephanie S. Handler, Susan Marjorie Richards, Catherine Anne Sheppard, Jenna Smith, Kathryn Tillman, Matthew Pietrosanu, Edward Kirkpatrick, Angela Bates University of Alberta and Stollery Children’s Hospital. Medical College of Wisconsin.Canada and United States Frontiers in PediatricsFront Pediatr 2023; DOI: 10.3389/fped.2023.1055131 AbstractIntroduction: Phosphodiesterase type 5 (PDE5) inhibitors, with sildenafil the earliest among them, are widely used

Multicenter review of a tadalafil suspension formulation for infants and children with pulmonary hypertension: A North American experience Read More »

Quantifying side effects and caregiver burdens of pediatric pulmonary hypertension therapies

Erik J. Nelson, Ella Cook, Samara Nelson, Rebecca Brown, Megan Pierce, Ashley Bangerter Seelos, Heather Stickle and Michael JohansenBrigham Young University. Utah State University. Indiana University School of Medicine. United States BioMed Central PediatricsBMC Pediatr 2023; 23: DOI: 10.1186/s12887-023-03860-2 AbstractBackground and objectives: Pulmonary hypertension (PH) is a rare, but serious disease among children. However, PH has been

Quantifying side effects and caregiver burdens of pediatric pulmonary hypertension therapies Read More »

Sotatercept for the Treatment of Pulmonary Arterial Hypertension

Marc Humbert, Vallerie McLaughlin, J. Simon R. Gibbs, Mardi Gomberg-Maitland, Marius M. Hoeper, Ioana R. Preston, Rogerio Souza, Aaron B. Waxman, Hossein-Ardeschir Ghofrani, Pilar Escribano Subias, Jeremy Feldman, Gisela Meyer, David Montani, Karen M. Olsson, Solaiappan Manimaran, Jennifer Barnes, Peter G. Linde, Janethe de Oliveira Pena, David B. BadeschPULSAR Trial Investigators.France, United States, United Kingdom,

Sotatercept for the Treatment of Pulmonary Arterial Hypertension Read More »

Scroll to Top